19 results on '"Holdenrieder, Stefan"'
Search Results
2. Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China.
- Author
-
Korse CM, Holdenrieder S, Zhi XY, Zhang X, Qiu L, Geistanger A, Lisy MR, Wehnl B, van den Broek D, Escudero JM, Standop J, Hu M, and Molina R
- Subjects
- Adult, Aged, Area Under Curve, Asian People, Carcinoma, Non-Small-Cell Lung blood, Carcinoma, Non-Small-Cell Lung ethnology, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Small Cell blood, Carcinoma, Small Cell ethnology, Carcinoma, Small Cell pathology, China, Diagnosis, Differential, Europe, Female, Humans, Lung Neoplasms blood, Lung Neoplasms ethnology, Lung Neoplasms pathology, Male, Middle Aged, Recombinant Proteins blood, Sensitivity and Specificity, White People, Biomarkers, Tumor blood, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Small Cell diagnosis, Immunoassay standards, Lung Neoplasms diagnosis, Peptide Fragments blood
- Abstract
Background: We performed a multicenter evaluation of the Elecsys® progastrin-releasing peptide (ProGRP) immunoassay in Europe and China., Methods: The assay was evaluated at three European and two Chinese sites by imprecision, stability, method comparison and differentiation potential in lung cancer., Results: Intermediate imprecision across five analyte concentrations ranged from 2.2% to 6.0% coefficient of variation. Good stability for plasma and serum samples was shown for various storage conditions. There was excellent correlation between the Elecsys® and ARCHITECT assays in plasma (slope 1.02, intercept -2.72pg/mL). The Elecsys® assay also showed good correlation between serum and plasma samples (slope 0.93, intercept 2.35pg/mL; correlation coefficient 0.97). ProGRP differentiated small-cell and non-small-cell lung cancer (NSCLC; area under the curve 0.90, 95% CI 0.87-0.93; 78.3% sensitivity, 95% specificity; at 84pg/mL), with no relevant effects of ethnicity, age, gender or smoking. Median ProGRP concentrations were low in benign diseases (38pg/mL), other malignancies (40pg/mL) or NSCLC (39pg/mL), except chronic kidney disease above stage 3 (>100pg/mL)., Conclusions: Increased stability of the Elecsys® ProGRP assay in serum and plasma offers clear benefits over existing assays. This first evaluation of a ProGRP assay in China demonstrated comparable differentiation potential among different ethnicities., (Copyright © 2014. Published by Elsevier B.V.)
- Published
- 2015
- Full Text
- View/download PDF
3. Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA between Immulite 2000 XPI and Dimension Vista 1500.
- Author
-
Zur B, Holdenrieder S, Walgenbach-Brünagel G, Albers E, and Stoffel-Wagner B
- Subjects
- Biomarkers, Tumor metabolism, Humans, Immunoassay standards, Luminescent Measurements standards, Neoplasms diagnosis, Reproducibility of Results, Carcinoembryonic Antigen blood, Immunoassay methods, Luminescent Measurements methods, Neoplasms blood, Prostate-Specific Antigen blood, alpha-Fetoproteins metabolism
- Abstract
Background: For the Luminescent Oxygen Channeling Immunoassay (LOCI) technology as established for Dimension Vista 1500, assays have been developed for the serum tumor markers AFP, CEA, PSA and free PSA. We performed a method analysis for these parameters using the Immulite 2000 XPI., Methods: Determination of within-day and total imprecision of the methods was carried out according to CLSI guidelines with three serum pools. In addition, parallel measurements were performed with both systems in 1,871 routine serum samples and correlations were calculated., Results: Calculated total imprecision of the three serum pools for AFP was 3.8 - 4.3%, for CEA 3.3 - 4.3%, for tPSA 3.6 - 4.0% and for fPSA it was 3.5 - 8.2%. Correlations of these markers across the entire value range were very good with the following correlation coefficients: 0.997 for AFP, 0.996 for CEA, 0.971 for tPSA and 0.988 for fPSA. While values for AFP and tPSA from both methods were comparable (slopes 1.02 and 1.01), lower values were measured for CEA and fPSA with the Dimension Vista (slopes 0.83 and 0.91). For AFP, a sample cluster with considerably higher values than with Dimension Vista was observed in the lower measurement range (< 20 ng/mL)., Conclusions: The assays for AFP, CEA, tPSA and fPSA, as developed with the LOCI technology for the Dimension Vista, show good comparability with results obtained from the Immulite 2000 XPI. However, lower measurement ranges for CEA and fPSA as well as individual divergences, especially with AFP, must be taken into consideration in the event of method changeover.
- Published
- 2012
4. Method comparison for CA 15-3, CA 19-9, and CA 125 determination using the new LOCI technique of Dimension Vista 1500 and Immulite 2000 XPI.
- Author
-
Zur B, Holdenrieder S, Albers E, Walgenbach-Brünagel G, and Stoffel-Wagner B
- Subjects
- Humans, Immunoassay instrumentation, Luminescent Measurements instrumentation, Oxygen chemistry, Biomarkers, Tumor blood, CA-125 Antigen blood, CA-19-9 Antigen blood, Immunoassay methods, Luminescent Measurements methods, Mucin-1 blood
- Abstract
We performed method comparison for the tumor markers CA 15-3, CA 19-9, and CA 125 measured by luminescent oxygen channeling immunoassay technology on the Dimension Vista 1500 and by classic luminescence technology on the Immulite 2000 XPI. Within-day and total imprecision were determined according to Clinical and Laboratory Standards Institute (CLSI) guidelines using three serum pools at different clinically relevant levels. In addition, parallel measurements on both systems were performed in a total of 738 routine serum samples (133 CA 15-3, 395 CA 19-9, and 210 CA 125). Total imprecision of serum pools for CA 15-3 ranged between 4.6% and 5.9%, for CA 19-9 between 4.4% and 7.8%, and for CA 125 between 3.3% and 4.3%. Marker values determined within the measurement range of both systems correlated well with each other (R = 0.88 for CA 15-3, R = 0.93 for CA 19-9, and R = 0.96 for CA 125). Slopes between the Vista and the Immulite method were 0.96 for CA 125, 0.72 for CA 15-3, and 0.87 for CA 19-9, indicating lower values for CA 15-3 and CA 19-9 when measured by the Vista method. This was particularly obvious for CA 19-9 levels in the lower measuring range of <100 U/mL (R = 0.85; slope 0.73).
- Published
- 2012
- Full Text
- View/download PDF
5. A multicenter assessment of the analytical performance of the routine thyroid panel on the Olympus AU3000i immunoassay system.
- Author
-
Bertsch T, Aschenneller C, Herzog V, Dupuy AM, Bargnoux AS, Badiou S, Ebel A, Winter A, Graf A, Rauch S, Durner J, Holdenrieder S, Fraunberger P, Gamble R, Sheridan B, Kukula J, Kenny P, and Cristol JP
- Subjects
- High-Throughput Screening Assays methods, Humans, Immunoassay methods, Sensitivity and Specificity, Thyrotropin blood, Thyroxine blood, Triiodothyronine blood, High-Throughput Screening Assays instrumentation, Immunoassay instrumentation, Thyroid Diseases blood
- Abstract
Background: The AU3000i thyroid assay panel (TSH, fT4, T4, fT3, T3) was evaluated at four sites in a European multicenter study. The study was designed to assess the basic analytical performance characteristics of the Olympus thyroid assays. In addition, a comprehensive assessment of the TSH functional sensitivity was undertaken to challenge the manufacturer's claim of 4th generation assay performance., Results: Repeatability (within-run precision) of TSH, ff4 and T4 was better than 3% across the measurable range, T3 and fT3 repeatability was better than 6%. Within-laboratory (total) precision was better than 10% for all assays, for fT4, it was better than 3%. Method comparisons were undertaken against the Roche Elecsys 2010, the Siemens Advia Centaur and the Abbott Architect. Overall, good to excellent correlations were seen, however in some cases there were systematic differences which can be attributed to the lack of an appropriate standard or reference method and/or heterogeneity of the analyte. The functional sensitivity of the Olympus TSH assay was confirmed to be 4th generation, giving a mean functional sensitivity (at 20% CV) of 0.0011 mIU/L with no sites exceeding 0.002 mIU/L. Plasma (Li-heparinate) was shown to be an acceptable sample type for use in these assays., Conclusion: The results generated in this study indicate that the assays of the Olympus AU3000i routine thyroid panel are precise, correlate well with other established assays, and are suitable for use in the routine clinical laboratory.
- Published
- 2009
6. Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel Dxl 800 Immunoassay System.
- Author
-
Stieber P, Molina R, Gion M, Gressner A, Troalen F, Holdenrieder S, Auge JM, Zancan M, Wycislo M, and Jarrige V
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Area Under Curve, Europe, Female, Humans, Immunoassay instrumentation, Male, Middle Aged, Pancreatic Neoplasms blood, Reproducibility of Results, Antibodies chemistry, CA-19-9 Antigen blood, Immunoassay methods, Pancreatic Neoplasms diagnosis
- Abstract
Background: Gastrointestinal cancer antigen CA19-9 is known as a valuable marker for the management of patients with pancreatic cancer., Methods: The analytical and clinical performance of the Access GI Monitor assay (Beckman Coulter) was evaluated on the UniCel Dxl 800 Immunoassay System at five different European sites and compared with a reference method, defined as CA19-9 on the Elecsys System (Roche Diagnostics)., Results: Total imprecision (%CV) of the GI Monitor ranged between 3.4% and 7.7%, and inter-laboratory reproducibility between 3.6% and 4.0%. Linearity upon dilution showed a mean recovery of 97.4% (SD + 7.2%). Endogenous interferents had no influence on GI Monitor levels (mean recoveries: hemoglobin 103%, bilirubin 106%, triglycerides 106%). There was no high-dose hook effect up to 115,000 kU/L. Clinical performance investigated in sera from 1811 individuals showed a good correlation between the Access GI Monitor and Elecsys CA19-9 (R = 0.959, slope = 1.004, intercept = +0.17). GI Monitor serum levels were low in healthy individuals (n = 267, median = 6.0 kU/L, 95th percentile=23.1 kU/L), higher in individuals with various benign diseases (n = 550, medians = 5.8-13.4 kU/L, 95th percentiles = 30.1-195.5 kU/L) and even higher in individuals suffering from various cancers (n = 995, medians = 8.4-233.8 kU/L, 95th percentiles = 53.7-13,902 kU/L). Optimal diagnostic accuracy for cancer detection against the relevant benign control group by the GI Monitor was found for pancreatic cancer [area under the curve (AUC) 0.83]. Results for the reference CA19-9 assay were comparable (AUC 0.85)., Conclusions: The Access GI Monitor provides very good methodological characteristics and demonstrates an excellent analytical and clinical correlation with the Elecsys CA19-9. The GI Monitor shows the best diagnostic accuracy in pancreatic cancer. Our results also suggest a clinical value of the GI Monitor in other cancers.
- Published
- 2008
- Full Text
- View/download PDF
7. Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel Dxl 800 Immunoassay System.
- Author
-
Holdenrieder S, Molina R, Gion M, Gressner A, Troalen F, Auge JM, Zancan M, Wycislo M, and Stieber P
- Subjects
- Europe, Female, Humans, Immunoassay instrumentation, Reference Standards, Reproducibility of Results, Sensitivity and Specificity, Antibodies blood, CA-125 Antigen analysis, Immunoassay methods, Ovarian Neoplasms diagnosis
- Abstract
Background: Cancer antigen CA125 is known as a valuable marker for the management of ovarian cancer., Methods: The analytical and clinical performance of the Access OV Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared with a reference system, defined as CA125 on the Elecsys System (Roche Diagnostics)., Results: Total imprecision (% CV) of the OV Monitor ranged between 3.1% and 8.8%, and inter-laboratory reproducibility between 4.7% and 5.0%. Linearity upon dilution showed a mean recovery of 100% (SD + 8.1%). Endogenous interferents had no influence on OV Monitor levels (mean recoveries: hemoglobin 107%, bilirubin 103%, triglycerides 103%). There was no high-dose hook effect up to 27,193 kU/L. Clinical performance investigated in sera from 1811 individuals showed a good correlation between the Access OV Monitor and Elecsys CA125 (R = 0.982, slope = 0.921, intercept = +1.951). OV Monitor serum levels were low in healthy individuals (n = 267, median = 9.7 kU/L, 95th percentile = 30.8 kU/L), higher in individuals with various benign diseases (n = 549, medians = 10.9-16.4 kU/L, 95th percentiles = 44.2-355 kU/L) and even higher in individuals suffering from various cancers (n = 995, medians = 12.4-445 kU/L; 95th percentiles = 53.4-4664 kU/L). Optimal diagnostic accuracy for cancer detection against the relevant benign control group by the OV Monitor was found for ovarian cancer [area under the curve (AUC) 0.898]. Results for the reference CA125 assay were comparable (AUC 0.899)., Conclusions: The Access OV Monitor provides very good methodological characteristics and demonstrates an excellent analytical and clinical correlation with Elecsys CA125. The best diagnostic accuracy for the OV Monitor was found in ovarian cancer. Our results also suggest a clinical value of the OV Monitor in other cancers.
- Published
- 2008
- Full Text
- View/download PDF
8. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System.
- Author
-
Molina R, Gion M, Gressner A, Troalen F, Auge JM, Holdenrieder S, Zancan M, Wycislo M, and Stieber P
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Area Under Curve, Breast Neoplasms blood, Europe, Female, Humans, Immunoassay instrumentation, Middle Aged, Ovarian Neoplasms blood, Reference Standards, Reproducibility of Results, Antibodies chemistry, Breast Neoplasms diagnosis, Immunoassay methods, Mucin-1 blood, Ovarian Neoplasms diagnosis
- Abstract
Background: Cancer antigen CA15-3 antigen is known as a valuable marker for the management of breast cancer., Methods: The analytical and clinical performance of the Access BR Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared with a reference system, defined as CA15-3 on the Elecsys System (Roche Diagnostics)., Results: Total imprecision (% CV) of the BR Monitor ranged between 5.5% and 11.7%, and inter-laboratory reproducibility between 3.4% and 5.1%. Linearity upon dilution showed a mean recovery of 98.5% (SD + 9.1%). Endogenous interferents had no influence on BR Monitor levels (mean recoveries: hemoglobin 112%, bilirubin 111%, triglycerides 108%). There was no high-dose hook effect up to 13,540 kU/L. Clinical performance investigated in sera from individuals showed a general correlation between the Access BR Monitor and Elecsys CA15-3 (R = 0.797), with a slope of 1.383. CA15-3 serum levels, as measured by the BR Monitor, were low in healthy individuals (n = 267, median = 11.9 kU/L, 95th percentile = 23.5 kU/L), higher in individuals with various benign diseases (n = 549, medians = 11.3-15.6 kU/L, 95th percentiles = 21.6-54.6 kU/L) and even higher in individuals suffering from various cancers (n = 995, medians = 11.2-22.8 kU/L, 95th percentiles = 30.0-429.7 kU/L). Best diagnostic accuracy for cancer detection against the relevant benign control group by the BR Monitor was found for locoregional and metastatic breast cancer, as well as for ovarian cancer [area under the curve (AUC) 0.619, 0.897 and 0.774]. Results for the reference CA15-3 assay were comparable (AUC 0.611, 0.887 and 0.818)., Conclusions: The Access BR Monitor provides accurate methodological characteristics and demonstrates an analytical and clinical correlation with Elecsys CA15-3. Best diagnostic accuracy for the BR Monitor was found in breast and ovarian cancer. Our results also suggest a clinical value of the BR Monitor in other cancers.
- Published
- 2008
- Full Text
- View/download PDF
9. High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood.
- Author
-
Krueger, Kimberly, Mayer, Zsuzsanna, Gerckens, Miriam, Boeck, Stefan, Luppa, Peter, and Holdenrieder, Stefan
- Subjects
PROGRAMMED death-ligand 1 ,PROGRAMMED cell death 1 receptors ,ENZYME-linked immunosorbent assay ,IMMUNOASSAY ,PLASMA displays - Abstract
Programmed death-1 receptor PD-1(CD279) and its corresponding ligands PD-L1(CD274, B7-H1) and PD-L2(CD273, B7-DC) play important roles in physiological immune tolerance and for immune escape in cancer disease. Hence, the establishment and analytical validation of a novel enzyme-linked immunosorbent assay (ELISA) to measure soluble PD-1, PD-L1 and PD-L2 in blood samples according to high quality standards is required. Antibody pairs were used to establish novel highly sensitive ELISAs for all three markers on an open electrochemiluminescence Quickplex platform. Analytical validation comprised intra- and interassay imprecision, limit of quantification, dilution linearity, material comparison and analytical selectivity testing. The methods demonstrated a broad dynamic range and precise measurements down to the pg/mL range. The coefficient of variation (CV) during the intra-assay imprecision measurements with three patient pools did not exceed 10% for all three assays (PD-1: 6.4%, 6.5%, 7.8%, PD-L1: 7.1%, 4.2%, 6.8%; PD-L2: 4.5%, 10.0%, 9.9%). Dilution linearity experiments in both buffer and heparin plasma displayed good linearity. Selectivity was shown for each marker in titration cross-reactivity experiments up to concentrations of at least 15 ng/mL of these, possibly confounding other markers. Soluble PD-1, PD-L1 and PD-L2 can be measured highly sensitively in serum and plasma and can safely be applied to clinical study settings. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. 一项在欧洲和中国进行的新型胃泌素释放肽前体(ProGRP)免疫检测多中心评估研究
- Author
-
KORSE, Catharina M., HOLDENRIEDER, Stefan, ZHI, Xiuyi, ZAHNG, Xiaotong, QIU, Ling, GEISTANGER, Andrea, LISY, Marcus-Rene, WEHNL, Birgit, van den BROEK, Daan, ESCUDERO, José M., STANDOP, Jens, HU, Mu, and MOLINA, Rafael
- Subjects
Adult ,Immunoassay ,Male ,China ,Lung Neoplasms ,Middle Aged ,Europe ,期刊博览 ,Gastrin-Releasing Peptide ,Gastrins ,Humans ,Female ,Protein Precursors ,Aged - Abstract
背景 在欧洲和中国进行Elecsys®胃泌素释放肽前体(ProGRP)免疫检测的多中心评估研究。方法 在欧洲的3个中心和中国的2个中心,在肺癌中,通过不精密度、稳定性、方法学比较和鉴别诊断能力来评价该检测法。结果 5个分析物浓度的中间不精密度范围为变异系数:2.2%-6.0%。在不同储存条件下,血浆和血清样本均显示出良好的稳定性。在血浆中Elecsys®和ARCHITECT检测(斜率1.02,截距-2.72 pg/mL)之间表现出良好的相关性。同时,Elecsys®检测在血清和血浆样本之间表现出良好的相关性(斜率0.93,截距2.35 pg/mL;相关系数0.97)。ProGRP作为不受种族、年龄、性别或吸烟史相关影响的检测手段,可鉴别小细胞和非小细胞肺癌(NSCLC);截断值为84 pg/mL时,曲线下面积为0.90,95%CI: 0.87-0.93;敏感性为78.3%,特异性为95%。ProGRP浓度中位数在良性病变(38 pg/mL)、其他恶性肿瘤(40 pg/mL)或NSCLC(39 pg/mL)中较低,而在3期以上慢性肾脏疾病中浓度较高(100 pg/mL)。结论 Elecsys® ProGRP检测在血清和血浆中稳定性增加,较现有检测法明显更具优势。ProGRP检测在中国的首次评价在不同种族中显示出相当的鉴别能力。.
- Published
- 2017
11. SARS-CoV-2 antibody testing—questions to be asked.
- Author
-
Özçürümez, Mustafa K., Ambrosch, Andreas, Frey, Oliver, Haselmann, Verena, Holdenrieder, Stefan, Kiehntopf, Michael, Neumaier, Michael, Walter, Michael, Wenzel, Folker, Wölfel, Roman, and Renz, Harald
- Abstract
Severe acute respiratory syndrome coronavirus 2 infection and development of coronavirus disease 2019 presents a major health care challenge of global dimensions. Laboratory diagnostics of infected patients, and the assessment of immunity against severe acute respiratory syndrome coronavirus 2, presents a major cornerstone in handling the pandemic. Currently, there is an increase in demand for antibody testing and a large number of tests are already marketed or are in the late stage of development. However, the interpretation of test results depends on many variables and factors, including sensitivity, specificity, potential cross-reactivity and cross-protectivity, the diagnostic value of antibodies of different isotypes, and the use of antibody testing in identification of acutely ill patients or in epidemiological settings. In this article, the recently established COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) addresses these issues on the basis of currently available data sets in this rapidly moving field. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Determinants of elevated carbohydrate antigen 125 in patients with severe symptomatic aortic valve stenosis referred for transcatheter aortic valve implantation.
- Author
-
Rheude, Tobias, Pellegrini, Costanza, Reinhard, Wibke, Trenkwalder, Teresa, Koenig, Wolfgang, Mayr, N. Patrick, Joner, Michael, Núñez, Julio, Holdenrieder, Stefan, Schunkert, Heribert, Kastrati, Adnan, Hengstenberg, Christian, and Husser, Oliver
- Subjects
AORTIC stenosis ,AORTIC valve diseases ,ANTIGENS ,IMMUNOASSAY ,ECHOCARDIOGRAPHY - Abstract
Purpose: Elevated carbohydrate antigen 125 (CA125) predicts adverse outcome after transcatheter aortic valve implantation (TAVI). While known underlying pathophysiological mechanisms of elevated CA125 include serosal effusions and inflammatory stimuli, clinical determinants associated with elevated CA125 in patients referred for TAVI remain unknown. Therefore, we investigated clinical, laboratory and echocardiographic determinants of elevated CA125 in patients with severe aortic valve stenosis referred for TAVI.Methods: This study includes 650 patients with severe aortic stenosis referred for TAVI. Baseline CA125 was determined by an immunoassay and dichotomized (elevated versus normal) based on the manufacturer cutoff value (>35 U/mL).Results: CA125 elevation was present in 28% (181/650). Patients with elevated CA125 had an overall worse clinical profile and were more symptomatic with a higher rate of NYHA class III/IV (80% versus 58%;p < 0.001). In a multivariate analysis, independent predictors of elevated CA125 were New York Heart Association (NYHA) class, baseline hemoglobin, C-reactive protein (CRP), left ventricular ejection fraction and severe tricuspid regurgitation.Conclusion: Elevated CA125 levels in patients referred for TAVI summarize a subset of patients with an overall worse clinical profile who are more symptomatic. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
13. Method comparison of tumor markers assessed by LOCI™- and ECLIA-based technologies.
- Author
-
Dolscheid-Pommerich, Ramona C., Dolscheid, Sarah, Eichhorn, Lars, Zur, Berndt, Holdenrieder, Stefan, and Stoffel-Wagner, Birgit
- Subjects
ALPHA fetoproteins ,COMPARATIVE studies ,STATISTICAL correlation ,IMMUNOASSAY ,IMMUNOLOGY technique ,LUMINESCENCE spectroscopy ,TUMOR markers ,PROSTATE-specific antigen ,ROUTINE diagnostic tests - Abstract
The article offers information on measurement of tumors using luminescent oxygen channeling immunoassays (LOCI™)-based assays and electrochemiluminiscent immunoassays (ECLIA). Topics discussed include determination of prostate cancer using prostate-specific antigen (PSA) and free PSA (fPSA); use of chemiluminescence immunoassay in LOCI™ technology; and correlations between α-fetoprotein (AFP), carcinoembryonic antigen (CEA) and prostate-specific antigen (PSA).
- Published
- 2017
- Full Text
- View/download PDF
14. Histone Methylation Marks on Circulating Nucleosomes as Novel Blood-Based Biomarker in Colorectal Cancer.
- Author
-
Gezer, Ugur, Yörüker, Ebru E., Keskin, Metin, Kulle, Cemil Burak, Dharuman, Yoganiranjana, and Holdenrieder, Stefan
- Subjects
COLON cancer ,HISTONE methylation ,NUCLEIC acids ,BIOMARKERS ,CHROMATIN - Abstract
Circulating nucleic acids (CNAs) are under investigation as a liquid biopsy in cancer as potential non-invasive biomarkers, as stable structure in circulation nucleosomes could be valuable sources for detection of cancer-specific alterations in histone modifications. Our interest is in histone methylation marks with a focus on colorectal cancer, one of the leading cancers respective the incidence and mortality. Our previous work included the analysis of trimethylations of lysine 9 on histone 3 (H3K9me3) and of lysine 20 on histone 4 (H4K20me3) by chromatin immuno- precipitation-related PCR in circulating nucleosomes. Here we asked whether global immunologic measurement of histone marks in circulation could be a suitable approach to show their potential as biomarkers. In addition to H3K9me3 and H4K20me3 we also measured H3K27me3 in plasma samples from CRC patients (n = 63) and cancer free individuals (n = 40) by ELISA-based methylation assays. Our results show that of three marks, the amounts of H3K27me3 (p = 0.04) and H4K20me3 (p < 0.001) were significantly lower in CRC patients than in healthy controls. For H3K9me3 similar amounts were measured in both groups. Areas under the curve (AUC) in receiver operating characteristic (ROC) curves indicating the power of CRC detection were 0.620 for H3K27me3, 0.715 for H4K20me3 and 0.769 for the combination of both markers. In conclusion, findings of this preliminary study reveal the potential of blood-based detection of CRC by quantification of histone methylation marks and the additive effect of the marker combination. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System
- Author
-
Holdenrieder, Stefan, Molina, Rafael, Gion, Massimo, Gressner, Axel, Troalen, Frédéric, Auge, Jose Maria, Zancan, Matelda, Wycislo, Matthias, and Stieber, Petra
- Subjects
- *
ANTIGENS , *IMMUNOGLOBULINS , *IMMUNOASSAY , *DIAGNOSIS , *HEMOGLOBINS - Abstract
Background: Cancer antigen CA125 is known as a valuable marker for the management of ovarian cancer. Methods: The analytical and clinical performance of the Access OV Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared with a reference system, defined as CA125 on the Elecsys System (Roche Diagnostics). Results: Total imprecision (%CV) of the OV Monitor ranged between 3.1% and 8.8%, and inter-laboratory reproducibility between 4.7% and 5.0%. Linearity upon dilution showed a mean recovery of 100% (SD+8.1%). Endogenous interferents had no influence on OV Monitor levels (mean recoveries: hemoglobin 107%, bilirubin 103%, triglycerides 103%). There was no high-dose hook effect up to 27,193 kU/L. Clinical performance investigated in sera from 1811 individuals showed a good correlation between the Access OV Monitor and Elecsys CA125 (R=0.982, slope=0.921, intercept=+1.951). OV Monitor serum levels were low in healthy individuals (n=267, median=9.7 kU/L, 95th percentile=30.8 kU/L), higher in individuals with various benign diseases (n=549, medians=10.9–16.4 kU/L, 95th percentiles=44.2–355 kU/L) and even higher in individuals suffering from various cancers (n=995, medians=12.4–445 kU/L; 95th percentiles=53.4–4664 kU/L). Optimal diagnostic accuracy for cancer detection against the relevant benign control group by the OV Monitor was found for ovarian cancer [area under the curve (AUC) 0.898]. Results for the reference CA125 assay were comparable (AUC 0.899). Conclusions: The Access OV Monitor provides very good methodological characteristics and demonstrates an excellent analytical and clinical correlation with Elecsys CA125. The best diagnostic accuracy for the OV Monitor was found in ovarian cancer. Our results also suggest a clinical value of the OV Monitor in other cancers. Clin Chem Lab Med 2008;46:588–99. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
16. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® BR Monitor assay on the UniCel® DxI 800 Immunoassay System
- Author
-
Molina, Rafael, Gion, Massimo, Gressner, Axel, Troalen, Frédéric, Auge, Jose Maria, Holdenrieder, Stefan, Zancan, Matelda, Wycislo, Matthias, and Stieber, Petra
- Subjects
IMMUNOGLOBULINS ,BIOMARKERS ,ANTIGENS ,MEDICAL laboratories ,IMMUNOASSAY - Abstract
Background: Cancer antigen CA15-3 antigen is known as a valuable marker for the management of breast cancer. Methods: The analytical and clinical performance of the Access
® BR Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared with a reference system, defined as CA15-3 on the Elecsys® System (Roche Diagnostics). Results: Total imprecision (%CV) of the BR Monitor ranged between 5.5% and 11.7%, and inter-laboratory reproducibility between 3.4% and 5.1%. Linearity upon dilution showed a mean recovery of 98.5% (SD±9.1%). Endogenous interferents had no influence on BR Monitor levels (mean recoveries: hemoglobin 112%, bilirubin 111%, triglycerides 108%). There was no high-dose hook effect up to 13,540 kU/L. Clinical performance investigated in sera from 1811 individuals showed a general correlation between the Access BR Monitor and Elecsys CA15-3 (R=0.797), with a slope of 1.383. CA15-3 serum levels, as measured by the BR Monitor, were low in healthy individuals (n=267, median=11.9 kU/L, 95th percentile=23.5 kU/L), higher in individuals with various benign diseases (n=549, medians=11.3–15.6 kU/L, 95th percentiles=21.6–54.6 kU/L) and even higher in individuals suffering from various cancers (n=995, medians=11.2–22.8 kU/L, 95th percentiles=30.0–429.7 kU/L). Best diagnostic accuracy for cancer detection against the relevant benign control group by the BR Monitor was found for locoregional and metastatic breast cancer, as well as for ovarian cancer [area under the curve (AUC) 0.619, 0.897 and 0.774]. Results for the reference CA15-3 assay were comparable (AUC 0.611, 0.887 and 0.818). Conclusions: The Access BR Monitor provides accurate methodological characteristics and demonstrates an analytical and clinical correlation with Elecsys CA15-3. Best diagnostic accuracy for the BR Monitor was found in breast and ovarian cancer. Our results also suggest a clinical value of the BR Monitor in other cancers. Clin Chem Lab Med 2008;46:612–22. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
17. Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific Enolase Enzyme Immunoassay.
- Author
-
Muley, Thomas, Ebert, Werner, Stieber, Petra, Raith, Hannelore, Holdenrieder, Stefan, Nagel, Dorothea, Fürst, Heinrich, Roth, Hans-Jürgen, Luthe, Hilmar, Blijenberg, Bert G., Gurr, Eberhard, Uhl, Wolfgang, Von Pawel, Joachim, and Drings, Peter
- Subjects
ENZYME-linked immunosorbent assay ,LUNG cancer ,BLOOD testing ,CANCER patients ,IMMUNOASSAY - Abstract
This international multicenter study was designed to evaluate the technical performance of the new double-monoclonal, single-step Elecsys neuron-specific enolase (NSE) enzyme immunoassay (EIA) and to assess its utility as a sensitive and specific test for the diagnosis of small-cell lung cancer (SCLC). Intra- and interassay coefficients of variation, determined in five control or serum specimens in six laboratories, ranged from 0.7 to 5.3 (inter-laboratory median: 1.3%) and from 1.3 to 8.5 (inter-laboratory median: 3.4%), respectively. Laboratory-to-laboratory comparability was excellent with respect to recovery and inter-assay coefficients of variation. The test was linear between 0.0 and 320 ng/ml (highest measured concentration). There was a significant correlation between NSE concentrations measured using the Elecsys NSE and the established Cobas Core NSE EIA II in all subjects (n = 723) and in patients with lung cancer (n = 333). However, NSE concentrations were systematically lower (approximately 9%) with the Elecsys NSE than with the comparison test. Based on a specificity of 95% in comparison with the group suffering from benign lung diseases (n = 183), the cut-off value for the discrimination between malignant and benign conditions was set at 21.6 ng/ml. NSE was raised in 73.4% of SCLC patients (n = 188) and was significantly higher (p < 0.01) in extensive (87.8%) as opposed to limited disease (56.7%). NSE was also elevated in 16.0% of the cases with non-small cell lung cancer (NSCLC, n = 374). It is concluded that the Elecsys NSE EIA is a reliable and accurate diagnostic procedure for the measurement of NSE in serum samples. The special merits of this new assay are the wide measuring range (according to manufacturer's declaration up to 370 ng/ml) and a short incubation time of 18 min. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
18. Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer.
- Author
-
Holdenrieder, Stefan, Molina, Rafael, Qiu, Ling, Zhi, Xiuyi, Rutz, Sandra, Engel, Christine, Kasper-Sauer, Pia, Dayyani, Farshid, and Korse, Catharina M.
- Subjects
SQUAMOUS cell carcinoma antigen ,HEAD & neck cancer diagnosis ,LUNG cancer ,CERVICAL cancer diagnosis ,BIOLOGICAL assay - Abstract
In squamous cell carcinoma, squamous cell carcinoma antigen levels are often elevated. This multi-center study evaluated the technical performance of a new Elecsys
® squamous cell carcinoma assay, which measures serum squamous cell carcinoma antigen 1 and 2 levels in an equimolar manner, and investigated the potential of squamous cell carcinoma antigen for differential diagnosis of cervical, lung, and head and neck squamous cell carcinoma.Assay precision and method comparison experiments were performed across three European sites. Reference ranges for reportedly healthy individuals were determined using samples from banked European and Chinese populations. Differential diagnosis experiments determined whether cervical, lung, or head and neck cancer could be differentiated from apparently healthy, benign, or other malignant cohorts using squamous cell carcinoma antigen levels alone. Squamous cell carcinoma antigen cut-off levels were calculated based on squamous cell carcinoma antigen levels at 95% specificity. Repeatability coefficients of variation across nine analyte concentrations were ≤5.3%, and intermediate precision coefficients of variation were ≤10.3%. Method comparisons showed good correlations with Architect and Kryptor systems (slopes of 1.1 and 1.5, respectively). Reference ranges for 95th percentiles for apparently healthy individuals were 2.3 ng/mL (95% confidence interval: 1.9–3.8; European cohort, n = 153) and 2.7 ng/mL (95% confidence interval: 2.2–3.3; Chinese cohort, n = 146). Strongest differential diagnosis results were observed for cervical squamous cell carcinoma: receiver operating characteristic analysis showed that squamous cell carcinoma antigen levels (2.9 ng/mL cut-off) differentiate cervical squamous cell carcinoma (n = 127) from apparently healthy females (n = 286; area under the curve: 86.2%; 95% confidence interval: 81.8–90.6; sensitivity: 61.4%; specificity: 95.6%), benign diseases (n = 187; area under the curve: 86.3%; 95% confidence interval: 81.2–91.3; sensitivity: 61.4%; specificity: 95.0%), and other cervical cancers (n = 157; area under the curve: 78.9%; 95% confidence interval: 70.8–87.1; sensitivity: 61.4%; specificity: 86.7%). Squamous cell carcinoma may also aid in the differential diagnosis of lung cancer. The Elecsys squamous cell carcinoma assay exhibited good technical performance and is suitable for differential diagnosis of cervical squamous cell carcinoma in clinical practice. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
19. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
- Author
-
Dolscheid-Pommerich, Ramona C., Keyver-Paik, Mignon, Hecking, Thomas, Kuhn, Walther, Hartmann, Gunther, Stoffel-Wagner, Birgit, and Holdenrieder, Stefan
- Subjects
IMMUNOASSAY ,CARCINOEMBRYONIC antigen ,CA 15-3 test ,BREAST cancer treatment ,OVARIAN cancer treatment - Abstract
Evidence is sparse regarding the clinical performance of luminescent oxygen channeling immunoassays–based tumor marker assays in gynecological cancer. Analyzing serum samples of 336 patients with Dimension™Vista1500, we investigated the diagnostic power of carbohydrate antigen 15-3, carbohydrate antigen 125, carcinoembryonic antigen, carbohydrate antigen 19-9, and alpha-fetoprotein in patients suffering from different types of gynecological cancer and precancerous gynecological diseases and compared findings to appropriate control groups. The cohort comprised 177 female patients with gynecological cancers (73 breast, 22 cervical, 16 endometrial, 17 vulva, and 49 ovarian cancers), 26 patients with precancerous gynecological diseases (11 vulva, 4 cervical, and 10 breast), 109 patients with benign gynecological diseases, and 24 healthy controls. Discriminative power was assessed by areas under the curve in receiver operating characteristic curves, and sensitivities were determined at a fixed specificity of 95%. Levels of biomarkers in healthy controls were in the expected ranges and a discriminative power between gynecological cancers and healthy controls was observed for several tumor markers. Established tumor type–associated markers were elevated in specific gynecological cancers and benign controls as well as within precancerous gynecological diseases and healthy control group. In ovarian cancer, carbohydrate antigen 125 and carbohydrate antigen 15-3 were significantly elevated compared to the respective benign diseases. Carbohydrate antigen 125 was the most conclusive marker (area under the curve = 0.86% and 77.6% sensitivity at 95% specificity). In breast cancer, carcinoembryonic antigen and carbohydrate antigen 15-3 were significantly higher than in the respective benign diseases. Carcinoembryonic antigen achieved the most conclusive area under the curve (0.65) with 31.5% sensitivity at 95% specificity. None of the investigated markers was found to be of value in discriminating benign and malignant cervical diseases. Carcinoembryonic antigen and alpha-fetoprotein distinguished precancerous breast and vulva diseases from healthy controls. These findings show that luminescent oxygen channeling immunoassays–based tumor marker assays provide reliable results in routine diagnostics. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.